ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ulcerative Colitis"

  • Abstract Number: 1093 • 2019 ACR/ARP Annual Meeting

    The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)

    Oleg Stens1, Charles Dillon 2, Frederick W. Miller 3 and Michael Weisman 4, 1Harbor-UCLA Medical Center, Torrance, CA, 2National Institutes of Health, Bethesda, MD, 3NIEHS, NIH, Bethesda, MD, 4David Geffen School of Medicine at UCLA, Los Angeles, CA

    Background/Purpose: Associations between ulcerative colitis (UC) and Crohn’s disease, known together as inflammatory bowel disease (IBD), with axial pain, inflammatory back pain (IBP) and spondyloarthritis…
  • Abstract Number: 367 • 2018 ACR/ARHP Annual Meeting

    Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors

    Bruno Emond1, Lorie A. Ellis2, Soumya D Chakravarty3, Martin Ladouceur1 and Patrick Lefebvre1, 1Analysis Group, Inc., Montréal, QC, Canada, 2Janssen Scientific Affairs, LLC, Horsham, PA, 3Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA

    Background/Purpose:  IBD is often associated with other CID, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Newer biologic agents…
  • Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting

    Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis

    Mark C. Genovese1, Jean-Frederic Colombel2, Amanda M. Gellett3, Wen Xu3 and Dana Hardin3, 1Department of Medicine, Stanford University, Palo Alto, CA, 2Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, 3Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…
  • Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting

    No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

    Atul A. Deodhar1, Stefan Schreiber2, Kunal Gandhi3, Todd Fox4, Corine Gaillez4 and Chetan Karyekar3, 1Oregon Health & Science University, Portland, OR, 2Christian-Albrechts-Universität Kiel, Kiel, Germany, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Novartis Pharma AG, Basel, Switzerland

    Background/Purpose:  Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
  • Abstract Number: 2142 • 2015 ACR/ARHP Annual Meeting

    Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs

    Elizabeth C. Hsia1,2, Neil Schluger3, John J. Cush4, Eric L. Matteson5, Stephen Xu1, William Sandborn6, Paul Rutgeerts7 and Colleen Marano1, 1Janssen Research & Development, LLC, Spring House, PA, 2University of Pennsylvania, Philadelphia, PA, 3Columbia U College of Physicians & Surgeons, New York, NY, 4Baylor Research Institute, Dallas, TX, 5Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 6Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, La Jolla, CA, 7University Hospital Gasthuisberg, Leuven, Belgium

    Background/Purpose:   Interferon-ƴ release assays (IGRAs) offer the possibility of an improved method to detect TB infections in pts with autoimmune disorders.  Compare results of…
  • Abstract Number: 2209 • 2014 ACR/ARHP Annual Meeting

    Novel Biomarkers of Extracellular Matrix Remodeling in Inflammatory Bowel Disease: Different Patterns of Gut Injury in UC and CD

    Joachim Høg Mortensen1, Line Elberg Godskesen2, Michael Dam Jensen2, Lone Gabriels Klinge2, Jens Kjeldsen2, Aleksander Krag2, Morten Karsdal3 and Anne C. Bay-Jensen4, 1Cartilage Biomarkers and Research, Nordic Bioscience, Købehavn, Denmark, 2Odense University Hospital, Odense, Denmark, 3Research & Development, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 4Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark

     Background/Purpose: About 10 % of patients with IBD have symptoms that match both Crohn's disease (CD) and ulcerative colitis (UC), termed inflammatory bowel disease unclassified…
  • Abstract Number: 805 • 2014 ACR/ARHP Annual Meeting

    Takayasu Arteritis and Ulcerative Colitis –High Concurrence Ratio and Genetic Overlap

    Chikashi Terao1, Takayoshi Matsumura2, Hajime Yoshifuji3, Yohei Kirino4, Yasuhiro Maejima5, Yoshikazu Nakaoka6, Meiko Takahashi1, Eisuke Amiya2, Natsuko Tamura5, Toshiki Nakajima3, Tomoki Origuchi7, Tetsuya Horita8, Mitsuru Matsukura2, Yuta Kochi2, Akiyoshi Ogimoto9, Motohisa Yamamoto10, Hiroki Takahashi11, Shingo Nakayamada12, Kazuyoshi Saito12, Yoko Wada13, Ichiei Narita13, Yasushi Kawaguchi14, Hisashi Yamanaka14, Koichiro Ohmura3, Tatsuya Atsumi8, Kazuo Tanemoto15, Tetsuro Miyata2, Masataka Kuwana16, Issei Komuro2, Yasuharu Tabara1, Atsuhisa Ueda17, Mitsuaki Isobe18, Tsuneyo Mimori3 and Fumihiko Matsuda1, 1Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 4Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Tokyo Medical and Dental University, Tokyo, Japan, 6Osaka University Graduate School of Medicine, Osaka, Japan, 7Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 9Ehime University Graduate School of Medicine, Ehime, Japan, 10Sapporo Medical University School of Medicine, Sapporo, Japan, 11First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, 12The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 13Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 14Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 15Kawasaki Medical School, Kurashiki, Japan, 16Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 17Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 18Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose . Takayasu arteritis (TAK) is a systemic vasculitis affecting large arteries and large branches of the aorta. Ulcerative colitis (UC) is a prevalent autoimmune…
  • Abstract Number: 2002 • 2013 ACR/ARHP Annual Meeting

    Prophylactic Duration and Serum Uric Acid Level Are Associated With Gout Flare During Urate Lowering Treatment

    Hyo-Jin Choi1, Chan Hee Lee2, Sang Tae Choi3, Jung-Soo Song3, Hyoun-Ah Kim4, Chang-Hee Suh5, Hoyeon Joo6, Ki Chul Shin7 and Hanjoo Baek1, 1Rheumatology, Gachon University Gil Hospital, Incheon, South Korea, 2Div Rheum Dept of Intl Med, NHIC Ilsan Hospital, Goyang-si, South Korea, 3Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, 4Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 5Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 7Rheumatology, Seoul National University College of Medicine, Seoul, South Korea

    Background/Purpose: To evaluate the clinical factors on gout flare during urate lowering treatment Methods: We retrospectively examined data derived from 228 patients who had been treated…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology